Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance!

Crit Care. 2020 Jun 10;24(1):325. doi: 10.1186/s13054-020-03058-3.

Authors

Teresa Maria Tomasa-Irriguible¹, Sergi Martínez-Vega², Ester Mor-Marco², Alba Herraiz-Ruiz², Laura Raguer-Pardo², Carlos Cubells-Larrosa³

Affiliations

¹ Intensive Care Medicine Department, Germans Trias i Pujol Hospital, Carretera del Canyet s/n, 08916 Badalona, Barcelona, Spain. teresatomasa@gmail.com.
² Intensive Care Medicine Department, Germans Trias i Pujol Hospital, Carretera del Canyet s/n, 08916 Badalona, Barcelona, Spain.
³ Anesthesiology Department, Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain.

No abstract available

Publication types

Case Reports

MeSH terms

COVID-19
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Coronavirus Infections / physiopathology*
Heparin, Low-Molecular-Weight / pharmacokinetics*
Humans
Male
Metabolic Clearance Rate
Middle Aged
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / physiopathology*
Renal Elimination / physiology*

Substances

Heparin, Low-Molecular-Weight